Tag Archive for: Telavant Holdings

TLA1 mode of action. In fibrosis, the compound's binding to its receptor induces TGF-beta and IL6 release. © Prometheus Biosciences/MSD
M&A

Roche acquires Telavant Holdings to win TLA1 race

Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.

Read more